Trial
NCT01557114
Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Collaborators
—
Condition
Malignant Melanoma
Intervention
Ipilimumab
Why stopped
New compounds available in the indication (nivolumab/pembrolizumab), toxicity of ipilimumab
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-09